U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07242092) titled 'Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs' on Sept. 19.
Brief Summary: This clinical trial aims to evaluate the effect of temporary methotrexate (MTX) discontinuation on the humoral immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adult patients with autoimmune rheumatic diseases (ARDs).
Key questions:
* Does suspending MTX for 2 weeks after PCV20 enhance humoral immunogenicity?
* What is the impact of MTX discontinuation on functional opsonophagocytic activity (OPA) and cellular immunity?
* What is the risk of disease flaring with MTX withdrawal?
...